You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of

    SBC: AARDEN PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of tuberculosis Aarden Pharmaceuticals Project Summary/Abstract The need exists for a new, breakthrough therapeutic for tuberculosis (TB). Current treatment regimens with toxic chemotherapeutic drugs are too long, causing poor compliance which results in reduced efficacy and the emer ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Intelligent and Automatic Image Segmentation Software for High ThroughputAnalysi

    SBC: CytoInformatics LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): It is well established that aging and many chronic diseases, such as cancer and heart failure, are associated with significant losses in skeletal muscle mass and strength in humans. There is agreement across the musclebiology community that important morphological characteristics of muscle fibers, such as fiber area, the number and position of myonuclei, cellul ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Proteomic differentiation of leukemia cells based on multiplexed arrays and mass

    SBC: TYMORA ANALYTICAL OPERATIONS LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Although some gene mutations can predict response to certain targeted therapies, single-gene testing has limits. Multiple important signaling pathways that may be the causes of human malignancy have continuously been discovered and dissected. Pathway and network diagnostic tests are challenging but are clearly on the way. Through this NIH STTR Phase I study, we ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. human Microvessel Culture System (hMCS)

    SBC: ANGIOMICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Human Microvessel Culture System (hMCS) Angiogenesis-targeting therapies, either inhibiting or promoting new vessel growth, have the potential for treating numerous diseases including cancer, eye diseases, cardiac and peripheral vascular disease, skin disorders, fibro-proliferative diseases, and inflammatory conditions such as arthritis. Furthermore, growing ev ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Epitaxial GaN on flexible metal tapes for low-cost transistor devices

    SBC: IBEAM MATERIALS, INC.            Topic: 1

    GaN-based devices are the basis of a variety of modern electronics applications, especially in optoelectronics and high-frequency / high-power electronics. These devices are based on epitaxial films grown on single-crystal wafers. The single-crystal wafer substrates are limiting because of their size, expense, mechanical properties and availability. If one could make GaN-based devices over large a ...

    STTR Phase I 2013 Department of EnergyARPA-E
  6. Harvesting specific plant metabolites from hairy root cultures using magnetized n

    SBC: NAPROGENIX, INC.            Topic: NCCIH

    DESCRIPTION: Plants produce a wide variety of valuable bioactive metabolites, but these are commonly present in low concentrations in the wild-type plant. This makes the separation and purification of these compounds complicated and expensive. The applicant company, Naprogenix Inc, has developed a technology for increasing the yields of specific bioactive metabolites in mutant plant cell cultures ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Mitochondrial Uncoupling as a Therapeutic Target in Obesity

    SBC: Nano-Mite Technologies, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Obesity is recognized as a national and global epidemic, as approximately 65% of adults in the United States are classified as overweight or obese as defined by body mass index (BMI). In fact, in the year 2000, the human race reached a historical landmark, when for the first time in history the number of adults with excess weight surpassed the number of those w ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Compounds for the Prevention and Treatment of Rhabdomyolysis

    SBC: Virtual Drug Development Inc.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this disease has 5-year relative survival rates of lt20%. Most lung cancers are non-small cell (NSCLC, 85% of cases). Curative surgery is not an option for the 80% of NSCLC patients who present with advanced s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Multi-Blot Western Device

    SBC: YC BIOELECTRIC LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): The long-term objective of this STTR project is to commercialize the protein multi-blot Western device, which contributes to improving the productivity and accuracy of conventional Western blot analysis. Although Western blotting has been used for more than three decades, this labor-and-cost demanding technique remains a key routine for a majority of life scien ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government